Showing 1 – 5 of 5
Relevance | Newest | Oldest |
  • Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy

    Abstract Full Text
    online first
    JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0578

    This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.

  • Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer

    Abstract Full Text
    open access has multimedia
    JAMA Surg. 2023; 158(10):1013-1021. 10.1001/jamasurg.2023.2840

    This cohort study investigates the association between the omission of axillary dissection and systemic therapy in patients with clinically node-positive breast cancer in the postneoadjuvant setting.

  • Risk Factors and Racial and Ethnic Disparities in Patients With Breast Cancer–Related Lymphedema

    Abstract Full Text
    free access
    JAMA Oncol. 2022; 8(8):1195-1200. 10.1001/jamaoncol.2022.1628

    This cohort study evaluate rates and risk factors associated with breast cancer–related lymphedema in patients treated with axillary lymph node dissection.

  • Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply

    Abstract Full Text
    JAMA Oncol. 2022; 8(6):942-943. 10.1001/jamaoncol.2022.0316
  • Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event

    Abstract Full Text
    free access
    JAMA Oncol. 2021; 7(12):1851-1855. 10.1001/jamaoncol.2021.4394

    This cohort study examines nodal recurrence rates in patients with clinically node-positive cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.